BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:

  • The Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:00 p.m. ET.



  • The 5th Annual Evercore ISI HealthCONx Conference (virtual) on Tuesday, November 29, 2022, at 8:25 a.m. ET.



  • The Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 8:30 a.m. ET.

Links to live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including oral factor D inhibitors BCX9930 and BCX10013, which are in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at .

BCRXW

Investor Contact:

John Bluth



Media Contact:

Catherine Collier Kyroulis





EN
09/11/2022

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE
Free
BCRX BioCryst Pharma...

ORLADEYO® (berotralstat) Approved in Colombia

ORLADEYO® (berotralstat) Approved in Colombia RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “Today’s announcement marks another important step toward bringing ORLADEYO to people living with HAE who are in need of new treatment options across the pan-Latin America region. Followin...

3h / 59m 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European...

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries ORLADEYO® (berotralstat) now reimbursed in the Netherlands RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major European countries, providing ...

June 6, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual...

June 3, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present New Data at 2025 Meeting of the European Academy o...

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.   BioCryst will present four abstracts at the meeting:  Impact of Berotralstat on Quality of Life among Patients with Heredit...

June 2, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) C...

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children initiating berotralstat in the APeX-P trial, and the broad safety and efficacy outcomes observed across all age groups of patient...

May 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch